Bagi R.P. Jana, MD
Department of General Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Professor, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2016 | University of Houston, Clear Lake, Clear Lake, TX, USA, MHA, Business |
| 2016 | University of Houston, Clear Lake, Clear Lake, TX, USA, MBA, Business |
| 1990 | Madras Medical College and General Hospital, Tamil Nadu, IND, MD, Medicine |
Postgraduate Training
| 1997-2000 | Clinical Fellowship, Medical Oncology and Hematology, Mount Sinai Medical Center, New York, NY |
| 1994-1997 | Clinical Residency, Christ Hospital and Medical Center, Chicago, IL |
| 1993-1994 | Clinical Internship, Pathology, Metropolitan Group Hospitals, University of Illinois, Chicago, IL |
| 1991-1993 | Senior House Officer, General Hospital, Tamil Nadu |
Board Certifications
| 2013 | Hematology, Diplomate |
| 2012 | Hospice and Palliative Care Medicine, Diplomate |
| 2010 | Medical Oncology, Diplomate |
Experience & Service
Academic Appointments
Professor, Department of General Oncology, The University of Texas Medical Branch, Galveston, TX, 2017 - 2018
Associate Professor, Department of General Oncology, The University of Texas Medical Branch, Galveston, TX, 2012 - 2017
Assistant Professor, The University of Texas Medical Branch, Galveston, TX, 2011 - 2012
Assistant Professor, The University of Centeral Florida College of Medicine, Orlando, FL, 2007 - 2011
Assistant Professor, University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, 2003 - 2007
Assistant Professor, Cancer Institute of Chennai, Chennai, 2001 - 2003
Instructor, Mount Sinai School of Medicine, New York, NY, 1997 - 2000
Selected Publications
Peer-Reviewed Articles
- Venkatesan R, Hirani N, Willis M, Jana B, Cheema Z. Impending Carotid Blowout From a Large Neck Mass Treated Sequentially With Endovascular Coil Embolization Followed by Induction Chemotherapy. J Oncol Pract 14(2):136-138, 2018. PMID: 29016223.
- Jana BR, Zhou Y. Novel Molecular Targets for the Therapy of Urothelial Cancer. Anticancer Res 35:4557-4567, 2015.
- Al Asad O, Salam A, Mannem S, Ninan M, Markowitz A, Jana B. Alternative therapy for Epstein Barr virus related hemophagocytic lymphohistiocytosis. Case Rep Oncol Med, 2015.
- Jana B, Khanfar A, Ninan M. Durable Hematological and Major Cytogenetic Response in a Patient with Isolated 20q Deletion Myelodysplastic Syndrome Treated with Lenalidomide. Case Reports in Oncological Medicine, 2014.
- Koshy J, Alperin J, Jana B, Markowitz A, Qian YW. A case of Philadelphia chromosome positive myeloproliferative neoplasm in a pregnant woman with unusual primary myelofibrosis features. Case Rep Hematol, 2013.
- Khanfar A, Trikha A, Bonds R, Jana B. Angioedema with normal C1q and C1 inhibitor: an atypical presentation of Waldenström macroglobulinemia. Int J Hem 97:654-6, 2013.
- 6. Ghadimi-Mahani M, McDonnold Mollie A, Jana B, Markowitz A, Willis M, Harirah H. Sarcomatoid carcinoma of the oral cavity during pregnancy. Case Reports in Perinatal Medicine 25, 2013.
- Jana BR, Galsky MD, Hahn NM, Milowsky MI, Sonpavde G. Novel molecular targets for the therapy of urothelial carcinoma 16:499-513, 2012.
- Khoury T, Mojica W, Hicks D. ERBB2 juxtamembrane domain (trastuzumab binding site) gene mutation is a rare event in invasive breast cancers overexpressing the ERBB2 gene. Mod Pathol 24:1055-9, 2011.
- Hicks DG, Janarthanan BR, Vardarajan R. The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence. BMC Cancer, 2010.
- Sood AK, Wang J, Mhawech-Fauceglia P, Jana B, Liang P, Geradts J.. Sam-pointed domain containing Ets transcription factor in luminal breast cancer pathogenesis. Cancer Epidemiol Biomarkers Prev, 2009.
- Seitz R, Ross D, Ring B. Validation of an immunohistochemical biomarker for identifying Her2+ patients at high risk of recurrence. Breast Cancer Research And Treatment:S248, 2007.
- Varadarajan R, Edge SB, Yu J, Watroba N, Janarthanan BR. Prognosis of occult breast carcinoma presenting as isolated axillary nodal metastasis. Oncology:456-9, 2006.
- Tan D, Wu X, Hou M. Interleukin-6 polymorphism is associated with more aggressive prostate cancer. J Urol 174:753-6, 2005.
- Berkelhammer C, Janarthan B, Bhagavan M, Schreiber S. Hepatocolic fistula and lower GI bleeding in hepatoma. Am J Gastroenterol:26254-6, 1996.
Abstracts
- Steinberg GD, Curti B, Sachdeva K, Katz MH, Jana B. Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer. Medscape, 2016.
- Ngishu R, Aterno M, Jana B. A case of refractory hemophagocytic lymphohistiocytosis in a young woman with systemic lupus erythematosus, 2016.
Book Chapters
- Bagi RP Jana, Sachdeva Kush. Adrenal Carcinoma Clinical Presentation. In: Medscape, 2016.
- Bagi RP Jana, Sachdeva Kush. Renal Transitional Cell Carcinoma. In: Medscape, 2016.
- Brendan Curti, Bagi RP Jana, Javeed Mansoor, Issam Makhoul, Kush Sachdeva. Renal Cell Carcinoma. In: Medscape, 2016.
- Sachdeva Kush, Jana Bagi RP. Nonseminoma Testicular Cancer Staging. In: Medscape, 2016.
- Sachdeva Kush, Jana Bagi RP. Seminoma Testicular Cancer Staging. In: Medscape, 2016.
- Kush S, Bagi J. Nonseminoma Testicular Cancer Treatment Protocols. In: Medscape, 2016.
- Sachdeva K, Curti B, Makhoul I, Jana B. Testicular Cancer. In: Medscape, 2016.
- Kush S, Makhoul I, Curti B, Jana B. In: Extragonadal Germ Cell Tumors, 2016.
- Steinberg GD, Curti B, Jana B, Jones JS, Katz MH, Levy DA, Sachdeva K. Cystoscopy Overview of Cystoscopy. In: Medscape, 2016.
- Steinberg GD, Brosman SA, Curti B, Jana B, Jiang Z, Stephen J, Jones, Katz MH, Levy DA, Lu D, Sachdeva K. Bladder Cancer. In: Medscape, 2016.
- Steinberg GD, Curti B, Sachdeva K, Katz MH, Jana B. Transurethral Resection of Bladder Tumors Overview of TURBT. In: Medscape, 2016.
- Steinberg GD, Curti B, Jana B, Katz MH, Sachdeva K. In: Urine Tumor Markers in Bladder Cancer Diagnosis, 2016.
- Jana B. Prostate Cancer Guidelines. In: Medscape, 2016.
Grant & Contract Support
| Title: | A Randomized, Phase II Efficacy Assessment Of Multiple Met-Kinase Inhibitors (Cabozantinib [Nsc #761968], Crizotinib [Nsc #749005], Savolitinib [Nsc #785348], And Sunitinib [Nsc #736511]) in Metastatic Papillary Renal Carcinoma |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | Prospective, Non-Interventional Study Of Disease Progression And Treatment of Patients With Polycythemia Vera In United States Academic Or Community Clinical Practices |
| Funding Source: | Incyte Corporation |
| Role: | Principal Investigator |
| Title: | Phase III Trial of Enzalutamide (Nsc 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | An Open-Label, Phase 1b Study of ACP-196 in Subjects with Multiple Myeloma Pharmaceutical Industry Study |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | Phase II-III Trial Of Adjuvant Radiotherapy And Androgen Deprivation Following Radical Prostatectomy With Or Without Adjuvant Docetaxel |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy PROSPER RCC |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | Everest: Everolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Diease Registry |
| Funding Source: | Celgene |
| Role: | Principal Investigator |
| Title: | Phase II Trial of Everolimus or Everolimus Plus Paclitaxel As First-Line Therapy In Cisplatin-Ineligible Participants with Advanced Urothelial Carcinoma |
| Funding Source: | Hoosier Oncology Group HOG Consortium Study |
| Role: | Principal Investigator |
| Title: | An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment Of Advanced Renal Cell Carcinoma (ADAPT) Pharmaceutical study Retrospective data analysis research |
| Funding Source: | Unknown |
| Role: | Co-Investigator |
| Title: | Study of Expression Patterns of Fortilin In Prostate And Breast Cancers And Its Association With Clinical Features, Prognosis And Treatment Outcome Pilot translational research project (pi initiated no funds) |
| Funding Source: | Unknown |
| Role: | Co-Investigator |
| Title: | A Randomized Phase II Study Of Androgen Deprivation Combined With Imc-A12versus Androgen Deprivation Alone For Patients With New Hormone-Sensitive Metastatic Prostate Cancer |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | A Randomized Phase II Study Of Androgen Deprivation Combined With Imc-A12versus Androgen Deprivation Alone For Patients With New Hormone-Sensitive Metastatic Prostate Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | Androgen Deprivation Therapy with or without Radium-223 Dichloride In Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases |
| Funding Source: | HOG Consortium Study |
| Role: | Co-Investigator |